Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Sales & Marketing
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — sales & marketing.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — sales & marketing?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — sales & marketing of $14.14M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — sales & marketing changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — sales & marketing increased by 30.4% year-over-year, from $10.84M to $14.14M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — sales & marketing?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — sales & marketing has grown at a 3.2% compound annual growth rate (CAGR), from $61.16M to $65.18M.
- What does gyre pharmaceuticals — sales & marketing mean?
- This encompasses the costs associated with promoting, advertising, and distributing the segment's pharmaceutical products to healthcare providers and patients. It provides insight into the company's investment in commercial infrastructure and market penetration efforts.